Botulin Toxin Use in Rosacea and Facial Flushing Treatment

Scala, Jacopo; Vojvodić, Aleksandra; Vojvodić, Petar; Vlaskovic-Jovicevic, Tatjana; Peric-Hajzler, Zorica; Matovic, Dusica; Dimitrijevic, Sanja; Vojvodić, Jovana; Sijan, Goran; Stepić, Nenad; Wollina, Uwe; Tirant, Michael; Thường, Nguyễn Văn; Fioranelli, Massimo; Lotti, Torello

doi:10.3889/oamjms.2019.784

Cited by 25 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Botox has been introduced as a therapeutic method in the treatment of rosacea: it seems its actions take place through the nervous system by lowering local vascularity, but the mode of action and efficacy are yet to be fully evaluated [41].…”

Section: Discussionmentioning

confidence: 99%

“…Some innate or acquired immune dysfunctions are often associated with several neurovascular dysfunctions, with a genetic component underlying the appearance of rosacea [42]. These dysfunctions are directly or indirectly associated Demodex Folliculorum (DF) (through its own bacteria endosymbiosis, or other bacteria unrelated to DF such as Staphylococcus), epidermidis, ultraviolet (UV) radiation, extreme temperatures, stress, congestive foods, and the presence of metabolic syndrome or diabetes mellitus [38][39][40][41]. DF has been shown to have Bacillus bacteria endosymbionts such as Bacillus Oleronius, Bacillus Pumilus, Bacilus simplex, Cereus or Corynebacterium kroppenstedtii [44][45][46].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Ardeleanu¹,

Moroianu²,

Constantin³

et al. 2020

JMMS

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory skin disease with a complex pathogenesis that mainly affects the central part of the face, with a global incidence of 5.46%. The present study was performed on a group of 68 patients with rosacea 1 and 2 subtypes, patients between 34-63 years old. The treatments were performed using a Cutera Xeo laser, using 2 types of probes: NdYag 1064nm for telangiectasias and LimeLight 520-1100nm for diffuse facial erythema, papules, and pustules, having an 10x30mm window. For patients with diffuse facial erythema, etc., the optimal number of sessions was between 3 and 6 with or without anesthetic cream, using energies between 14-19J / cm. The average recovery time was 5 days. Registered effects included bruises, pustules, burning sensation, transient stinging, and hypopigmentation. For patients with telangiectasia, the optimal number of sessions was two, performed at an average interval of once per month/ monthly.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Ardeleanu¹,

Moroianu²,

Constantin³

et al. 2020

JMMS

View full text Add to dashboard Cite

show abstract

“…BTX has multiple non-cosmetic uses, including prevention of hypertrophic scars, amelioration of flushing in rosacea, improvement of localized pruritic dermatoses, and treatment of dermatoses aggravated by sweating. 166,167 Challenges in dermatology…”

Section: The Future Of Dermocosmeticsmentioning

confidence: 99%

“…As such, dermatologists should expect an increasing number of enquiries from patients regarding BTX. BTX has multiple non‐cosmetic uses, including prevention of hypertrophic scars, amelioration of flushing in rosacea, improvement of localized pruritic dermatoses, and treatment of dermatoses aggravated by sweating 166,167 …”

Section: Overview Of Workhopsmentioning

confidence: 99%

Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019

Luger

Dirschka

Eyerich

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

The 2019 Interactive Derma Academy (IDeA) meeting was held in Lisbon, Portugal, 10–12 May, bringing together leading dermatology experts from across Europe, the Middle East and Asia. Over three days, the latest developments and challenges in relation to the pathophysiology, diagnosis, evaluation and management of dermatological conditions were presented, with a particular focus on acne, atopic dermatitis (AD) and actinic keratosis (AK). Interesting clinical case studies relating to these key topics were discussed with attendees to establish current evidence‐based best practices. Presentations reviewed current treatments, potential therapeutic approaches and key considerations in the management of acne, AK and AD, and discussed the importance of the microbiome in these conditions, as well as the provision of patient education/support. It was highlighted that active treatment is not always required for AK, depending on patient preferences and clinical circumstances. In addition to presentations, two interactive workshops on the diagnosis and treatment of sexually transmitted infections/diseases (STIs/STDs) presenting to the dermatology clinic, and current and future dermocosmetics were conducted. The potential for misdiagnosis of STIs/STDs was discussed, with dermoscopy and/or reflectance confocal microscopy suggested as useful diagnostic techniques. In addition, botulinum toxin was introduced as a potential dermocosmetic, and the possibility of microbiome alteration in the treatment of dermatological conditions emphasized. Furthermore, several challenges in dermatology, including the use of lasers, the complexity of atopic dermatitis, wound care, use of biosimilars and application of non‐invasive techniques in skin cancer diagnosis were reviewed. In this supplement, we provide an overview of the presentations and discussions from the fourth successful IDeA meeting, summarizing the key insights shared by dermatologists from across the globe.

show abstract

“…Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of acetylcholine at the neuromuscular junction level. 10 Besides its effects on muscles, the blockade of acetylcholine release from peripheral autonomic nerves of the cutaneous vasodilatory system could inhibit the release of inflammatory mediators such as substance P and calcitonin gene-related peptide (CGRP), which have a relevant effect on vasodilation 11 and also reduce skin inflammation by directly inhibiting mast cell degranulation. 12 Based on the effects on blood vessels and inflammation, BTX injection has been progressively applied on rosacea patients with refractory erythema and flushing.…”

Section: Introductionmentioning

confidence: 99%

Willingness-to-Pay and Benefit–Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey

Yang¹,

Ouyang²,

Deng³

et al. 2021

PPA

View full text Add to dashboard Cite

Purpose Botulinum toxin (BTX) is a new treatment approach primarily aimed at relieving flushing and erythema for rosacea, but it is expensive and lacks economic benefit evaluation studies.This study aimed to investigate willingness-to-pay (WTP) of BTX treatment and conduct benefit–cost analysis (BCA) to assess if BTX treatment for rosacea is recommendable from a viewpoint of economics in China. Methods WTP of BTX treatment in rosacea and information of sociodemographic and clinical characteristics were inquired via an online questionnaire among the Chinese rosacea patients. The WTP was inquired by photos of three cases with different severities of rosacea before and after BTX treatment. The benefit–cost ratio (BCR) was calculated by dividing WTP by cost. Factors associated with WTP were identified using logistic regression models. Results The average costs of BTX treatment were USD410.09. The mean WTP for Case 1, Case 2, and Case 3 was USD295.53, 307.91, and 311.78, respectively (p<0.05 for Case 1 vs Case 3). 44.31% to 47.52% of Chinese rosacea patients were willing to pay for the BTX treatment. The BCRs were 0.72, 0.75, and 0.76 for Case 1, Case 2, and Case 3, respectively. A positive correlation between WTP and visiting frequency in the past year (OR=1.181–1.200, p=0.015–0.032, for Cases 1 and 2) or Dermatology Life Quality Index (DLQI) score (OR=2.022–2.266, all p<0.01) was observed, but duration (OR=0.521–0.564, p<0.05, for Cases 1 and 2) of rosacea was negatively correlated with WTP. Conclusion For rosacea patients with poor quality of life, and those with high visiting frequency, BTX should be regarded as a recommendable new treatment in China.

show abstract

Botulin Toxin Use in Rosacea and Facial Flushing Treatment

Cited by 25 publications

References 19 publications

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

The use of NDYAG laser combined with pulsed light in the treatment of rosacea

Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019

Willingness-to-Pay and Benefit–Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey

Contact Info

Product

Resources

About